Finance

Allos Therapeutics Reports Net Loss In Third Quarter

Published in Cancer Weekly, November 27th, 2001

Allos Therapeutics, Inc., (ALTH) reported that for the three months ended September 30, 2001, the company showed a net loss of $5.1 million, or $0.22 per share. This compares with a net loss of $3.6 million, or $0.16 per share, for the same quarter in 2000. The company recorded $0.9 million, or $0.04 per share in amortization of deferred stock compensation for the same three months, which is included in the net loss for the period.

For the 9 months ended September 30, 2001, the company reported a net loss of $14.8 million, or $0.64 per share, compared with a net loss of $18.4 million, or $1.13 per share, for the same period last year. Included in the net loss for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry